Free tool
FAERS Monitor: Trileptal
Last checked: Nov 19, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021014 or its brand name (Trileptal, Oxcarbazepine). Reports on generic versions are filed under their own applications.
Reports
31,740
Serious
24,137
76% of reports
Hospitalization
9,889
Death reported
2,192
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- drug ineffective2,931
- seizure2,829
- off label use1,726
- dizziness1,533
- fatigue1,465
- convulsion1,455
- nausea1,317
- headache1,301
- somnolence1,251
- fall1,208
- hyponatraemia1,183
- vomiting1,131
- drug interaction1,055
- rash1,003
- depression951
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 631 |
| 2005 | 749 |
| 2006 | 782 |
| 2007 | 779 |
| 2008 | 722 |
| 2009 | 1,057 |
| 2010 | 1,058 |
| 2011 | 1,110 |
| 2012 | 1,389 |
| 2013 | 1,153 |
| 2014 | 1,247 |
| 2015 | 1,809 |
| 2016 | 1,930 |
| 2017 | 1,761 |
| 2018 | 1,893 |
| 2019 | 1,919 |
| 2020 | 1,795 |
| 2021 | 1,803 |
| 2022 | 1,644 |
| 2023 | 1,758 |
| 2024 | 1,747 |
| 2025 | 1,711 |
| 2026 | 1,290 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,022,419 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| convulsionSignal | 1,455 | 17.3 | 16.4 | 21,785 |
| seizureSignal | 2,829 | 16.6 | 16.0 | 40,700 |
| hyponatraemiaSignal | 1,183 | 14.2 | 13.4 | 14,233 |
| drug interactionSignal | 1,055 | 4.4 | 4.2 | 2,800 |
| somnolenceSignal | 1,251 | 4.1 | 3.9 | 2,982 |
| depressionSignal | 951 | 2.8 | 2.6 | 1,087 |
| fallSignal | 1,208 | 2.4 | 2.3 | 1,008 |
| dizzinessSignal | 1,533 | 2.0 | 1.9 | 829 |
| vomiting | 1,131 | 1.6 | 1.5 | 256 |
| rash | 1,003 | 1.5 | 1.4 | 185 |
| drug ineffective | 2,931 | 1.5 | 1.4 | 476 |
| headache | 1,301 | 1.4 | 1.3 | 137 |
| off label use | 1,726 | 1.3 | 1.2 | 129 |
| fatigue | 1,465 | 1.2 | 1.2 | 74 |
| nausea | 1,317 | 1.1 | 1.0 | 13 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.